TAMOXIFEN AS ADJUVANT THERAPY IN BREAST-CANCER - CURRENT STATUS

Authors
Citation
Pn. Plowman, TAMOXIFEN AS ADJUVANT THERAPY IN BREAST-CANCER - CURRENT STATUS, Drugs, 46(5), 1993, pp. 819-833
Citations number
95
Language
INGLESE
art.tipo
Review
Categorie Soggetti
Pharmacology & Pharmacy",Toxicology
Journal title
DrugsACNP
ISSN journal
0012-6667
Volume
46
Issue
5
Year of publication
1993
Pages
819 - 833
Database
ISI
SICI code
0012-6667(1993)46:5<819:TAATIB>2.0.ZU;2-9
Abstract
Tamoxifen retains its place as the most important drug in the manageme nt of human breast cancer. As time passes, it becomes clear that this drug is no longer to be regarded as a simple antiestrogen, since it mo difies other cellular signalling mechanisms, giving scientific credenc e to the growth inhibitory effects observed in estrogen receptor-negat ive tumours. With the role of tamoxifen in breast cancer being well do cumented, recent interest has concentrated on its now proven efficacy in adjuvant treatment of patients with the disease in its early stages , and on its prophylactic role in women at high risk of developing the disease. For tamoxifen to have any role at all in the latter situatio n, it must be demonstrably safe, and here again the toxicity profile i s now much better understood.